| P2093 | author name string | Xin Xu | |
| | Xiao Wang | |
| | Xiangyi Zheng | |
| | Jiangfeng Li | |
| | Haiyun Xie | |
| | Huaqing Yan | |
| | Yufan Ying | |
| P2860 | cites work | Bias in meta-analysis detected by a simple, graphical test | Q24685585 |
| | Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement | Q27860606 |
| | Operating characteristics of a rank correlation test for publication bias | Q27860653 |
| | Meta-analysis in clinical trials | Q27860779 |
| | Pioglitazone utilization, efficacy & safety in Indian type 2 diabetic patients: A systematic review & comparison with European Medicines Agency Assessment Report | Q33568852 |
| | A retrospective study on finding correlation of pioglitazone and incidences of bladder cancer in the Indian population | Q33750513 |
| | Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta-analysis | Q34065266 |
| | Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes. | Q34671802 |
| | Pioglitazone use and risk of bladder cancer: population based cohort study | Q34676639 |
| | Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting | Q35043204 |
| | Pioglitazone and bladder cancer: a population-based study of Taiwanese. | Q35688201 |
| | The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study | Q36001145 |
| | Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study | Q36013549 |
| | Pioglitazone and the risk of bladder cancer: An Indian retrospective cohort study | Q36050377 |
| | Dose effect of thiazolidinedione on cancer risk in type 2 diabetes mellitus patients: a six-year population-based cohort study. | Q53060957 |
| | Intrinsic subtypes and bladder cancer metastasis. | Q55078504 |
| | Possible link of pioglitazone with bladder cancer in Japanese patients with type 2 diabetes | Q85642529 |
| | Diabetes mellitus and risk of bladder cancer: a meta-analysis of cohort studies | Q86316589 |
| | Use of thiazolidinediones and risk of bladder cancer: disease or drugs? | Q86701036 |
| | The peroxisome proliferator activated receptor gamma agonist pioglitazone increases functional expression of the glutamate transporter excitatory amino acid transporter 2 (EAAT2) in human glioblastoma cells | Q36356318 |
| | The risk of bladder cancer in korean diabetic subjects treated with pioglitazone. | Q36365241 |
| | On random-effects meta-analysis | Q36377499 |
| | Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study | Q36486802 |
| | Pioglitazone and bladder cancer: a propensity score matched cohort study | Q36562522 |
| | Rosiglitazone Use and the Risk of Bladder Cancer in Patients With Type 2 Diabetes. | Q36581133 |
| | Diabetes Pharmacotherapies and Bladder Cancer: A Medicare Epidemiologic Study | Q36712191 |
| | Epidemiology of urinary bladder cancer: from tumor development to patient's death | Q36832297 |
| | Pioglitazone after Ischemic Stroke or Transient Ischemic Attack | Q36953272 |
| | Comparing pioglitazone to insulin with respect to cancer, cardiovascular and bone fracture endpoints, using propensity score weights | Q37115436 |
| | Pioglitazone use and risk of bladder cancer in patients with type 2 diabetes: retrospective cohort study using datasets from four European countries | Q37179822 |
| | The association of pioglitazone and urinary tract disease in type 2 diabetic Taiwanese: bladder cancer and chronic kidney disease | Q37464712 |
| | Risk of bladder cancer among patients with diabetes treated with a 15 mg pioglitazone dose in Korea: a multi-center retrospective cohort study. | Q37583052 |
| | Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis | Q38417421 |
| | A population-based cohort study in Taiwan--use of insulin sensitizers can decrease cancer risk in diabetic patients? | Q38429541 |
| | Pioglitazone and the Risk of Bladder Cancer: A Meta-Analysis | Q38721611 |
| | Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends. | Q38876950 |
| | The combinatory effects of PPAR-γ agonist and survivin inhibition on the cancer stem-like phenotype and cell proliferation in bladder cancer cells | Q38995735 |
| | Higher expression of peroxisome proliferator-activated receptor γ or its activation by agonist thiazolidinedione-rosiglitazone promotes bladder cancer cell migration and invasion | Q39177047 |
| | Role of peroxisome proliferator activated receptor-gamma in bacillus Calmette-Guérin bladder cancer therapy | Q39255088 |
| | Comparative safety of pioglitazone versus clinically meaningful treatment alternatives concerning the risk of bladder cancer in older US adults with type 2 diabetes | Q40141299 |
| | Ten-year observational follow-up of PROactive: a randomized cardiovascular outcomes trial evaluating pioglitazone in type 2 diabetes | Q41107308 |
| | Effects of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on the urine and urothelium of the rat. | Q43254579 |
| | Pioglitazone use and the risk of bladder cancer. | Q43526947 |
| | Risk of bladder cancer in diabetic patients treated with rosiglitazone or pioglitazone: a nested case–control study | Q44980532 |
| | Proteinuria testing among patients with diabetes mellitus is associated with bladder cancer diagnosis: potential for unmeasured confounding in studies of pioglitazone and bladder cancer. | Q45947012 |
| | Pioglitazone prescription increases risk of bladder cancer in patients with type 2 diabetes: an updated meta-analysis. | Q45974480 |
| | Effects of PPAR agonists on proliferation and differentiation in human urothelium | Q46525079 |
| | An updated meta-analysis of pioglitazone exposure and bladder cancer and comparison to the drug's effect on cardiovascular disease and non-alcoholic steatohepatitis | Q47583526 |
| | Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial | Q47691659 |
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1627-1638 | |
| P577 | publication date | 2018-06-22 | |
| P1433 | published in | Cancer Management and Research | Q5031417 |
| P1476 | title | Pioglitazone use in patients with diabetes and risk of bladder cancer: a systematic review and meta-analysis | |
| P478 | volume | 10 | |